Table 3.

Dosimetric comparison.

Structure	Parameter	Plan (mean ± SD)			Overall	Multiple comparison
						1 vs. 2	1 vs. 3	2 vs. 3
		1. No boost	2. DIL_40	3. DIL_45	P-value	P-value
DIL	D95% (Gy)	35.67 ± 1.49	38.85 ± 0.80	42.89 ± 1.09	< 0.001	0.001	0.001	0.001
Prostate	D95% (Gy)	35.09 ± 0.60	35.10 ± 0.81	35.23 ± 0.68	0.725	0.443	0.778	0.887
PTV	D99% (Gy)	31.10 ± 0.81	30.95 ± 1.36	29.88 ± 1.43	0.008	0.842	0.036	0.009
	Dmax (Gy)	39.45 ± 0.22	41.94 ± 2.44	45.77 ± 1.50	< 0.001	0.001	0.001	0.002
	CO	91.18 ± 2.28	89.46 ± 3.69	88.67 ± 4.13	0.109	0.115	0.081	0.393
	CI	1.20 ± 0.04	1.20 ± 0.07	1.35 ± 0.12	< 0.001	0.483	0.001	0.001
Rectum	Dmax (Gy)	33.28 ± 0.39	34.96 ± 1.48	37.15 ± 3.44	< 0.001	0.001	0.001	0.003
	D30.8 Gy	0.70 ± 0.20	1.00 ± 1.23	2.14 ± 2.67	0.127	0.02	0.036	0.256
Bladder	Dmax (Gy)	36.46 ± 1.05	37.31 ± 0.83	39.13 ± 2.07	< 0.001	0.006	0.001	0.013
	D35.7 Gy (cc)	0.41 ± 0.30	0.46 ± 0.30	1.17 ± 1.50	0.155	0.691	0.023	0.053
Urethra	Dmax (Gy)	37.78 ± 0.17	39.27 ± 0.91	41.8 ± 2.16	< 0.001	< 0.001	< 0.001	< 0.001
Number of nodes		358 (291–387)	377 (291–416)	316 (190–456)	0.063	0.242	0.122	0.042
Treatment time per fraction (minutes)		71 (65–73)	72 (65–75)	70 (51–79)	0.191	0.214	0.313	0.122

CI conformity index, CO tumor coverage, DIL dominant intraprostatic lesion, PTV planning target volume.